Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
INTRODUCTION: Understanding the pneumococcal serotypes causing community-acquired pneumonia (CAP) is essential for evaluating the impact of pneumococcal vaccines. METHODS: We conducted a prospective surveillance study of adults aged ≥18 years hospitalized with CAP at 3 hospitals in Tennessee and Georgia between 1 September 2018 and 31 October 2022. We assessed for pneumococcal etiology with cultures, the BinaxNOW urinary antigen detection test, and serotype-specific urinary antigen detection assays that detect 30 pneumococcal serotypes contained in the investigational pneumococcal conjugate vaccine V116, as well as licensed vaccines PCV15 and PCV20 (except serotype 15B). The distribution of pneumococcal serotypes was calculated based on serotype-specific urinary antigen detection results. RESULTS: Among 2917 hospitalized adults enrolled with CAP, 352 (12.1%) patients had Streptococcus pneumoniae detected, including 51 (1.7%) patients with invasive pneumococcal pneumonia. The 8 most commonly detected serotypes were: 3, 22F, 19A, 35B, 9N, 19F, 23A, and 11A. Among 2917 adults with CAP, 272 (9.3%) had a serotype detected that is contained in V116, compared to 196 (6.7%) patients with a serotype contained in PCV20 (P < .001), and 168 (5.8%) patients with a serotype contained in PCV15 (P < .001). A serotype contained in V116 but not PCV15 or PCV20 was detected in 120 (4.1%) patients, representing 38.0% of serotype detections. CONCLUSIONS: Approximately 12% of adults hospitalized with CAP had S. pneumoniae detected, and approximately one-third of the detected pneumococcal serotypes were not contained in PCV15 or PCV20. Development of new pneumococcal vaccines with expanded serotype coverage has the potential to prevent a substantial burden of disease.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prevalence, Clinical Severity, and Serotype Distribution of Pneumococcal Pneumonia Among Adults Hospitalized With Community-Acquired Pneumonia in Tennessee and Georgia, 2018–2022
- Date Crossref
- 17/07/2024
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Vanderbilt University Medical Center Department of Emergency Medicine pays non établi dans la noticeÉtablissement de santé
-
Inc. Merck & Co. pays non établi dans la noticeEntreprise
-
Emory University Department of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Yale University Department of Pediatrics pays non établi dans la noticeUniversité ou école supérieure
-
VA Tennessee Valley Healthcare System pays non établi dans la noticeÉtablissement de santé
-
Geriatric Research Education and Clinical Center Education pays non établi dans la noticeÉtablissement de santé
-
Value & Implementation pays non établi dans la noticeInstitution
-
Global Health Institute and Rollins School of Public Health pays non établi dans la noticeUniversité ou école supérieure
-
Yale School of Public Health Department of Epidemiology of Microbial Diseases pays non établi dans la noticeUniversité ou école supérieure
Department of Emergency Medicine — Vanderbilt University Medical Center, Merck & Co. — Inc. et Department of Medicine — Emory University, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.